Medical equipment and pharmaceutical supplier McKesson (NYSE: MCK) is set to report earnings on January 31. While investors wait for the earnings results, the stock is facing resistance in the form of the upper rail of a downward sloped trend channel. The channel started back in late April and connects the highs from then, June, October, and November. The lower rail connects the lows from April, July/August, and December.
If the resistance holds and the stock makes another trip down to the lower rail, it would put the stock down below the $100 mark. McKesson hasn’t been under $100 since early 2013, but the trend has been to the downside since the stock hit an all-time high of $236.52 back in May 2015.
The company’s fundamentals are mixed with a decent return on equity, but slow earnings growth, sales growth, and a low profit margin. The company’s ROE is 25.3% and that is the highlight among the fundamental indicators. Earnings have only grown at a rate of 2% per year over the last three years while sales have grown at a rate of 4% during that same timeframe. It isn’t helping earnings that the company sports a profit margin of only 1.7%.
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
The 10-day moving average for MCK crossed bullishly above the 50-day moving average on October 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 01, 2026. You may want to consider a long position or call options on MCK as a result. In 59 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
The Moving Average Convergence Divergence (MACD) for MCK just turned positive on October 05, 2026. Looking at past instances where MCK's MACD turned positive, the stock continued to rise in 36 of 53 cases over the following month. The odds of a continued upward trend are 68%.
MCK moved above its 50-day moving average on October 01, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for MCK moved above the 200-day moving average on September 03, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +2.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where MCK advanced for three days, in 258 of 387 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MCK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.
MCK broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MCK entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MCK's P/B Ratio (-59.961) is very low in comparison to the industry average of (2.488). P/E Ratio (22.969) is within average values for comparable stocks, (39.020). Projected Growth (PEG Ratio) (1.616) is also within normal values, averaging (2.016). Dividend Yield (0.004) settles around the average of (0.004) among similar stocks. P/S Ratio (0.265) is also within normal values, averaging (4.260).
The Tickeron Profit vs. Risk Rating rating for this company is 13 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. MCK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 70 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a distributer of pharmaceuticals and provides healthcare software and health information technology services
Industry MedicalDistributors